Repurposed Drugs Show Promise for Alcohol Use Disorder Treatment | AUD News

A fresh gaze at existing medications, combined with advanced data analysis, is offering a potential pathway to better treatment options for alcohol use disorder (AUD). Researchers are exploring whether drugs already approved for other conditions could be repurposed to address AUD, a condition affecting an estimated 28.9 million adults in the United States in 2023. This approach is particularly promising given the limited number of FDA-approved medications specifically for AUD – currently just three – and their often-uneven effectiveness.

The Challenge of Current Treatments

The three medications currently approved by the FDA for AUD – disulfiram, acamprosate, and naltrexone – have demonstrated varying degrees of success, and their uptake in clinical practice remains low. Studies suggest that these pharmacotherapies are under-utilized, potentially due to a combination of factors including clinician unfamiliarity and a lack of optimal treatment strategies. The necessitate for innovation in this area is clear, and repurposing existing drugs offers a potentially faster route to new therapies than developing entirely new compounds.

The new approach focuses on aligning genomic data with clinical health records to identify drugs that might be effective in treating AUD. This involves analyzing how genes interact with alcohol and its effects on the body, and then matching those genetic signatures with the known effects of existing medications. The goal is to identify drugs that can counteract the biological processes underlying AUD.

A New Endpoint for Clinical Trials

Alongside this drug repurposing effort, the Food and Drug Administration (FDA) has recently qualified a new tool to facilitate clinical trials for AUD treatments. The FDA’s Center for Drug Evaluation and Research (CDER) announced the qualification of a tool based on a two-level reduction in risk drinking level (RDL). So that clinical trials can now use a reduction in RDL as a primary endpoint, alongside traditional measures like abstinence or heavy drinking days.

Reducing risk drinking levels – the amount of alcohol consumed that puts an individual at risk of health problems – is a clinically meaningful goal for many patients with AUD. The FDA’s qualification of this new endpoint could make it easier to conduct clinical trials and accelerate the development of new treatments. It provides researchers with more flexibility in how they measure the effectiveness of potential therapies.

Understanding Risk Drinking Levels

The concept of “risk drinking level” is central to this new approach. It’s a way of quantifying alcohol consumption based on the potential for harm. Whereas specific thresholds vary depending on factors like gender and body weight, a higher RDL indicates a greater risk of alcohol-related health problems. The FDA-qualified tool focuses on achieving a two-level reduction in RDL, which has been validated as a significant clinical improvement.

Currently, only a small percentage of individuals with AUD receive treatment. Statistics from the National Center for Drug Abuse Statistics (NCDAS) indicate that less than 8% of the 29.8 million individuals with AUD receive any form of treatment. This highlights the urgent need for more effective and accessible treatment options.

How Drug Repurposing Works and Its Limitations

Drug repurposing, also known as drug repositioning, isn’t a new concept. It involves identifying new uses for existing drugs. This approach can significantly reduce the time and cost associated with drug development, as the safety profile of the drug is already established. However, it’s not without its challenges. A drug that works well for one condition may not be effective for another, and dosage requirements may differ. Intellectual property rights can sometimes complicate the process.

The genomic data analysis component of this new approach adds a layer of precision to drug repurposing. By identifying the specific genes and biological pathways involved in AUD, researchers can target drugs that are most likely to have a beneficial effect. This is a more targeted approach than simply screening existing drugs at random.

What’s Next for AUD Treatment Development?

The FDA’s qualification of the new clinical trial endpoint and the ongoing research into drug repurposing represent important steps forward in the fight against AUD. The next phase will involve conducting clinical trials to evaluate the effectiveness of repurposed drugs and to refine the use of the new RDL endpoint. Researchers will also continue to explore the genetic basis of AUD to identify new drug targets.

Further research is needed to understand the long-term effects of reducing RDLs and to determine which patients are most likely to benefit from this approach. The FDA will continue to review data from clinical trials and to update its guidance as new information becomes available. Individuals concerned about their alcohol consumption should consult with a qualified healthcare professional for personalized advice and treatment options.

The development of drug development tools, like the RDL endpoint, plays a crucial role in bringing new therapies to market. These tools, which include biomarkers and clinical outcome assessments, help researchers to evaluate the effectiveness of potential treatments more efficiently and accurately. The hope is that these advancements will ultimately lead to more effective and accessible care for individuals struggling with AUD.